H&P Labs Receives Financial contribution from the Government of Canada for new antiviral program

MONTREAL, May 11, 2015 /CNW/ - H&P Labs Inc. today announced it will receive technical and business advisory services, as well as a financial contribution of up to $350,000 from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP).

This investment will support the development of new antivirals to fight viral infections such as Ebola, Lassa Fever and Chikungunya.

"The development of new antivirals is in line with our strategy to expand our product portfolio and continue to develop treatment options against life-threatening viruses," said John Huss, President and CEO of H&P Labs Inc. "We would sincerely like to thank NRC-IRAP for their continued support and encouragement."

About H&P Labs:
H&P Labs is a private biotechnology company focused on the development of drugs to fight infectious viral diseases worldwide for public health and biodefense missions. H&P Labs' objective is to deliver treatment options against Viral Hemorrhagic Fevers (VHFs), such as Ebola, Lassa, Dengue, as well as other important and often life-threatening viruses (e.g., MERS, Chikungunya, EEE/WEE/VEE).
www.hnplabs.com

SOURCE H&P Labs

John Huss, President & CEO, Tel: [phone] x3321, [email protected]; Media: Scott Anderson, TMX Equicom, Tel: [phone] x 252, [email protected]